You are here

  • Home
  • Archive
  • Volume 58, Issue 1
  • Does antidepressant medication in patients with hepatitis C undergoing interferon α treatment reduce therapeutic efficacy?

Article Text

Article menu
Download PDFPDF
Letter
Does antidepressant medication in patients with hepatitis C undergoing interferon α treatment reduce therapeutic efficacy?
  1. G Robaeys1,
  2. M C Wichers2,
  3. J De Bie3,
  4. G H Koek4,
  5. F Buntinx5,6,
  6. J Van Os2,7
  1. 1
    Department of Gastroenterology and Hepatology, Ziekenhuis Oost Limburg, Genk, Belgium
  2. 2
    Department of Psychiatry and Neuropsychology, South Limburg Mental Health Research and Teaching Network, EURON, Maastricht University, Maastricht, The Netherlands
  3. 3
    Department of Psychiatry, Ziekenhuis Oost Limburg, Genk, Belgium
  4. 4
    Department of Internal Medicine, Section of Gastroenterology and Hepatology, Academic Hospital Maastricht (AZM), The Netherlands
  5. 5
    Department of General Practice, Katholieke Universiteit Leuven, Leuven, Belgium
  6. 6
    Department of General Practice, Maastricht University, Maastricht, The Netherlands
  7. 7
    Division of Psychological Medicine, Institute of Psychiatry, London, UK
  1. Dr M C Wichers, Department of Psychiatry and Neuropsychology, South Limburg Mental Health Research and Teaching Network, EURON, Maastricht University, Maastricht, The Netherlands; m.wichers{at}sp.unimaas.nl

https://doi.org/10.1136/gut.2008.156919

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Activation of the inflammatory immune system, as evidenced by the effects of interferon α (IFNα) treatment, induces depressive symptoms. Prescription of a selective serotonin reuptake inhibitor (SSRI) is now advocated in combination with antiviral therapy in patients exposed to IFNα when early symptoms of depression emerge. The recently published article written by Kraus et al (Gut 2008;57:531–6) gives further evidence for the efficacy of SSRIs to treat depressive symptoms during IFNα treatment.

    The mechanisms by which SSRIs reduce depressive symptoms remain unclear. Several hypotheses, such as impact on serotonin activity or neurotrophic actions, have been proposed. Another, that has good face validity in this context, is that the anti-inflammatory properties of SSRIs mediate at least in part the decrease in depressive symptoms. Antidepressants have been shown in …

    View Full Text

    Footnotes

    • GR and MCW contributed equally to this work.

    • Funding: Dr MC Wichers was supported by the Dutch Medical Council (VENI grant no. 916.76.147)

    • Competing interests: None.

    • GR and MCW contributed equally to this work.

    Linked Articles

    • Letter
      Authors’ response
      M R Kraus A Schäfer M Scheurlen
      Gut 2008; 58 145-146 Published Online First: 17 Dec 2008.